Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Seeking Alpha
Helen Torley - President, CEO & Director Conference Call Participants Michael DiFiore - Evercore ISI Institutional Equities, Research Division Presentation Michael DiFiore Evercore ISI Institutional Equities, Research Division Okay. Let's get started. Welcome, everybody. Welcome to our conference in Miami. I had the pleasure of having Dr. Helen Torley, CEO of Halozyme Therapeutics. Helen, welcome. Thanks so much for making time for us. Before we delve into Q&A, I'd love to get your overview of the business and maybe key things to look forward to in the next 12 months or so. Helen Torley President, CEO & Director That's great. Well, thanks for the invitation, Mike. Pleased to be here. This really is an incredibly exciting time at Halozyme. When you think about the amazing adoption that we're seeing for argenx's VYVGART Hytrulo prefilled syringe, being used by patients at home. On the back of the phenomenal success of DARZALEX subcu, where 96% of patients in the U.S
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]Seeking Alpha
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]Yahoo! Finance
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in GermanyPR Newswire
- Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.MarketBeat
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 11/24/25 - Form 8-K
- HALO's page on the SEC website